Parametrica Management Ltd buys $1,286,756 stake in TESARO Inc (TSRO)

TESARO Inc (TSRO) : Parametrica Management Ltd scooped up 8,277 additional shares in TESARO Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 22, 2016. The investment management firm now holds a total of 13,988 shares of TESARO Inc which is valued at $1,286,756.TESARO Inc makes up approximately 1.84% of Parametrica Management Ltd’s portfolio.

Other Hedge Funds, Including , Cutler Group Lp reduced its stake in TSRO by selling 6,198 shares or 66.5% in the most recent quarter. The Hedge Fund company now holds 3,122 shares of TSRO which is valued at $264,402. TESARO Inc makes up approx 0.02% of Cutler Group Lp’s portfolio.

TESARO Inc closed down -0.38 points or -0.41% at $93.24 with 13,57,118 shares getting traded on Friday. Post opening the session at $93, the shares hit an intraday low of $91.18 and an intraday high of $93.829 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, TESARO Inc reported $-2.22 EPS for the quarter, missing the analyst consensus estimate by $ -0.54 based on the information available during the earnings call on May 5, 2016. Analyst had a consensus of $-1.68. The company had revenue of $.31 million for the quarter, compared to analysts expectations of $3.54 million. During the same quarter in the previous year, the company posted $-1.30 EPS.

Many Wall Street Analysts have commented on TESARO Inc. Robert W. Baird Initiated TESARO Inc on Jul 19, 2016 to “Outperform”, Price Target of the shares are set at $105.Company shares were Reiterated by Mizuho on Jul 5, 2016 to “Buy”, Firm has raised the Price Target to $ 94 from a previous price target of $67 .TESARO Inc was Downgraded by Jefferies to ” Hold” on Jun 30, 2016.

TESARO Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates rolapitant niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1 or NK-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib formerly known as MK-4827 is an orally active and potent poly (ADP-ribose) polymerase and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio Inc. for the discovery and development of antibodies for several specified immuno-oncology targets.

Leave a Reply

TESARO Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on TESARO Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.